Thymidylate synthase (TS) is an indispensable enzyme in the de novo synthesis of dTMP in dividing cells. As such, it is an excellent target at which anti-cancer drugs are directed. A number of pharmacological agents, such as 5-fluoropyrimidines (e.g., 5-fluorouracil and 5-fluoro-2'-deoxyuridine) and folic acid analogs (e.g., raltitrexed and BW1843U89), are cytotoxic to proliferating cells as a consequence of their ability to generate metabolites that inhibit TS. It has long been recognized that treatment of cells or tumors with TS inhibitors results in induction of the enzyme's concentration. Such induction has been viewed as a primary mechanism for the emergence of cellular resistance to these inhibitors, and, therefore, as an obstacle to effective chemotherapeutic response. Our laboratory has shown that the induction of TS in drug-exposed cells is due to stabilization of the enzyme by the binding of inhibitory ligands. Building on crystal structures of human TS, along with recent experiments indicating that the enzyme is degraded by the 26S proteasome, we have proposed a molecular mechanism for ligand-mediated stabilization of the TS polypeptide. We postulate that the ligand-free enzyme, which exhibits a disordered conformation in the region between residues 107-128, is readily ubiquitinated and targeted to the 26S proteasome; it is therefore unstable and expressed at low levels. The ligand-bound enzyme, on the other hand, becomes ordered in the 107-128 region, which decreases ubiquitination and allows """"""""escape"""""""" from the proteasome; this results in stabilization of the enzyme, and higher levels of expression. In the present grant, we propose experiments that will rigorously test this model. We will determine if TS is ubiquitinated in a ligand-dependent manner (AIM 1). In addition, we will establish whether or not ubiquitination is critical to proteasome-mediated degradation of the TS polypeptide (AIMS 2, 3). Finally, we will assess the role(s) of the disordered region and nearby lysine residues (AIMS 4-6). The proposed experiments will provide novel information on the role of TS turnover in regulating the enzyme's function as a drug target. As such, they will have application in the use of TS inhibitors as anti-cancer agents, and will be useful in designing high expressing TS genes for protection of normal tissues against the toxic effects of these inhibitors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA044013-16
Application #
6931088
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
1990-03-01
Project End
2007-07-31
Budget Start
2005-08-01
Budget End
2006-07-31
Support Year
16
Fiscal Year
2005
Total Cost
$181,250
Indirect Cost
Name
University of South Carolina at Columbia
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
111310249
City
Columbia
State
SC
Country
United States
Zip Code
29208
Ozer, Ufuk; Barbour, Karen W; Clinton, Sarah A et al. (2015) Oxidative Stress and Response to Thymidylate Synthase-Targeted Antimetabolites. Mol Pharmacol 88:970-81
Barbour, Karen W; Xing, Yang-Yang; Pena, Edsel A et al. (2013) Characterization of the bipartite degron that regulates ubiquitin-independent degradation of thymidylate synthase. Biosci Rep 33:165-73
Zhang, Xinna; Wan, Guohui; Berger, Franklin G et al. (2011) The ATM kinase induces microRNA biogenesis in the DNA damage response. Mol Cell 41:371-83
Davis, Celestia; Price, Robert; Acharya, Grishma et al. (2011) Hematopoietic derived cell infiltration of the intestinal tumor microenvironment in Apc Min/+ mice. Microsc Microanal 17:528-39
Melo, Sandra P; Barbour, Karen W; Berger, Franklin G (2011) Cooperation between an intrinsically disordered region and a helical segment is required for ubiquitin-independent degradation by the proteasome. J Biol Chem 286:36559-67
Zhang, Xinna; Wan, Guohui; Mlotshwa, Sizolwenkosi et al. (2010) Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 70:7176-86
Melo, Sandra P; Yoshida, Asami; Berger, Franklin G (2010) Functional dissection of the N-terminal degron of human thymidylate synthase. Biochem J 432:217-26
Peña, Maria Marjorette O; Melo, Sandra P; Xing, Yang-Yang et al. (2009) The intrinsically disordered N-terminal domain of thymidylate synthase targets the enzyme to the ubiquitin-independent proteasomal degradation pathway. J Biol Chem 284:31597-607
Barbour, Karen W; Berger, Franklin G (2008) Cell death in response to antimetabolites directed at thymidylate synthase. Cancer Chemother Pharmacol 61:189-201
Berger, F G; Kramer, D L; Porter, C W (2007) Polyamine metabolism and tumorigenesis in the Apc(Min/+) mouse. Biochem Soc Trans 35:336-9

Showing the most recent 10 out of 22 publications